The Value of Progesterone for the Timing of the Embryo Transfer in IVF/ICSI: a Prospective Randomised Trial

Not Applicable

Completed

• Conditions: Clinical Pregnancy Rate

• Registration Number: NCT03162315
• Lead Sponsor: University Hospital, Ghent

Brief Summary

At the start of the controlled ovarian stimulation as a part of the IVF/ICSI treatment patients are informed about this trial. In case they gave informed consent and they have a progesterone level between 1 and 1.5 ng/ml at the day of the hCG injection, they will be randomised. One group of patients will have a fresh embryo transfer, in the second group all embryos will be cryopreserved and transfered in a subsequent (natural or artificial) cycle. The aim of this study is to compare clinical pregnancy rate between the two groups.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-03
• Study First Submitted: 2016-03-23
• Study First Submitted QC: 2017-05-19
• Study First Posted: 2017-05-22
• Primary Completion: 2018-08-03
• Study Completion: 2018-08-03
• Status Verified: 2019-10
• Last Update Submitted: 2020-03-31
• Last Update Posted: 2020-04-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 24

Inclusion Criteria

• IVF/ICSI treatment
• progesterone > 1 ng/ml and ≤ 1.5 ng/ml

Exclusion Criteria

• > 40 years
• AMH ≤ 1 ng/ml
• Conditions influencing pregnancy rate (e.g. hydrosalphinx, uterus malformation, hyperprolactinemia and other endocrine conditions; with the exception of controlled thyroid function disease)
• no available progesterone value on the day of hCG-injection

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Clinical pregnancy rate	7 gestational weeks

Secondary Outcome Measures

Name	Time	Method
Ongoing pregnancy rate	25 gestational weeks
Live birth rate	Delivery

Trial Locations

Locations (1)

Ghent University Hospital - Department of Reproductive Medicine; 🇧🇪 Ghent, Belgium